ALPS Advisors’s AbbVie ABBV Stock Holding History

ALPS Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28M	Buy	128,678 +6,990	+6%	+$1.55M	0.13%	88
2025 Q4	$27.8M	Sell	121,688 -179	-0.1%	-$40.8K	0.16%	71
2025 Q3	$28.2M	Sell	121,867 -44,294	-27%	-$9.02M	0.16%	67
2025 Q2	$30.8M	Buy	166,161 +8,673	+6%	+$1.61M	0.18%	56
2025 Q1	$33M	Sell	157,488 -25,234	-14%	-$4.91M	0.19%	51
2024 Q4	$32.5M	Buy	182,722 +15,506	+9%	+$2.85M	0.2%	54
2024 Q3	$33M	Sell	167,216 -34,372	-17%	-$6.41M	0.22%	53
2024 Q2	$34.6M	Buy	201,588 +4,577	+2%	+$758K	0.24%	36
2024 Q1	$35.9M	Sell	197,011 -26,090	-12%	-$4.5M	0.25%	37
2023 Q4	$34.6M	Sell	223,101 -3,822	-2%	-$557K	0.27%	36
2023 Q3	$33.8M	Sell	226,923 -11,287	-5%	-$1.66M	0.28%	35
2023 Q2	$32.1M	Buy	238,210 +803	+0.3%	+$118K	0.28%	36
2023 Q1	$37.8M	Buy	237,407 +3,371	+1%	+$515K	0.33%	30
2022 Q4	$37.8M	Sell	234,036 -26,024	-10%	-$3.99M	0.34%	33
2022 Q3	$34.9M	Buy	260,060 +13,421	+5%	+$1.93M	0.33%	38
2022 Q2	$37.8M	Buy	246,639 +45,894	+23%	+$7.01M	0.37%	30
2022 Q1	$32.5M	Sell	200,745 -29,387	-13%	-$4.27M	0.35%	33
2021 Q4	$31.2M	Sell	230,132 -4,807	-2%	-$568K	0.35%	33
2021 Q3	$25.3M	Buy	234,939 +4,183	+2%	+$478K	0.24%	58
2021 Q2	$26M	Buy	230,756 +3,518	+2%	+$396K	0.23%	59
2021 Q1	$24.6M	Buy	227,238 +18,548	+9%	+$1.98M	0.24%	67
2020 Q4	$22.4M	Sell	208,690 -11,228	-5%	-$1.08M	0.25%	63
2020 Q3	$19.3M	Sell	219,918 -8,582	-4%	-$808K	0.28%	60
2020 Q2	$22.4M	Sell	228,500 -60,275	-21%	-$5.31M	0.3%	52
2020 Q1	$22M	Sell	288,775 -140,221	-33%	-$11.9M	0.34%	52
2019 Q4	$38M	Sell	428,996 -97,800	-19%	-$8.12M	0.3%	48
2019 Q3	$39.9M	Buy	526,796 +35,558	+7%	+$2.44M	0.31%	42
2019 Q2	$35.7M	Sell	491,238 -35,184	-7%	-$2.77M	0.26%	85
2019 Q1	$42.4M	Buy	526,422 +30,929	+6%	+$2.53M	0.3%	44
2018 Q4	$45.7M	Buy	495,493 +474,055	+2,211%	+$41.7M	0.35%	38
2018 Q3	$2.03M	Buy	21,438 +809	+4%	+$76.7K	0.01%	251
2018 Q2	$1.91M	Sell	20,629 -2,095	-9%	-$205K	0.01%	233
2018 Q1	$2.15M	Buy	22,724 +10,945	+93%	+$1.2M	0.02%	208
2017 Q4	$1.14M	Sell	11,779 -531,104	-98%	-$50.1M	0.01%	238
2017 Q3	$48.2M	Sell	542,883 -141,910	-21%	-$10.8M	0.34%	52
2017 Q2	$49.7M	Sell	684,793 -42,094	-6%	-$2.83M	0.35%	34
2017 Q1	$47.4M	Buy	726,887 +100,586	+16%	+$6.32M	0.33%	50
2016 Q4	$39.2M	Buy	626,301 +129,125	+26%	+$7.88M	0.29%	39
2016 Q3	$31.4M	Buy	497,176 +53,930	+12%	+$3.49M	0.26%	57
2016 Q2	$27.4M	Buy	443,246 +56,506	+15%	+$3.44M	0.24%	50
2016 Q1	$22.1M	Buy	386,740 +24,879	+7%	+$1.39M	0.23%	70
2015 Q4	$21.4M	Buy	+361,861	New	+$20.8M	0.21%	41
2014 Q4	–	Sell	-295,274	Closed	-$17.1M	–	585
2014 Q3	$17.1M	Buy	295,274 +26,334	+10%	+$1.46M	0.13%	59
2014 Q2	$15.2M	Buy	268,940 +52,747	+24%	+$2.77M	0.13%	50
2014 Q1	$11.1M	Buy	216,193 +26,580	+14%	+$1.34M	0.11%	93
2013 Q4	$9.34M	Buy	+189,613	New	+$9.32M	0.09%	90

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ALPS Advisors's ABBV Position: Q1 2026 in Review

ALPS Advisors increased its AbbVie (ABBV) stake by 5.7% in Q1 2026, buying an estimated $1.55M and bringing the position to 128,678 shares worth $28M. The position accounts for 0.13% of the portfolio, ranked #88.

ALPS Advisors first reported a position in ABBV in Q4 2013 and has held it in 46 quarters since. The position peaked at $49.7M in Q2 2017. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

ALPS Advisors held 128,678 shares of AbbVie worth $28M as of Q1 2026.
ALPS Advisors bought 6,990 AbbVie shares in Q1 2026, an estimated $1.55M.
AbbVie made up 0.13% of ALPS Advisors's portfolio in Q1 2026, its #88 holding.
ALPS Advisors first reported a position in AbbVie in Q4 2013 and has held it in 46 quarters since.
ALPS Advisors's AbbVie position peaked at $49.7M in Q2 2017.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.